A Phase 4 interventional study of Vitamin B12, Vitamin B6, Folic acid and Vitamin B12 (Cyanocobalamin) in Vitamin B12 Deficiency, sponsored by Medice Arzneimittel Pütter GmbH & Co KG. Completed at 2 sites in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Medice Arzneimittel Pütter GmbH & Co KG · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency — 1 open to participants now, 2 under way, 2 of them phase 3. Vitamin B 12 · Vitamin B 12 Deficiency.
Among the 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency, this one is the 10th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 14th registered.
73 studies on the registry are indexed under Vitamin B 12 Deficiency; 8 are open to participants now.
Browse Vitamin B 12 Deficiency studies →1 of the 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency is open now, in 1 country. Recruiting first, the newest first:
Sykehuset Innlandet HF · Sites in Norway
Ages 1 mo–2 mo
By country, each count listing its studies:
Vitamin B 12: first FDA approval 1947 (BEROCCA PN). What it is approved for, and how studies give it, is on its page →
Of the 2 Vitamin B 12 Deficiency studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
This study's enrollment of 46 is below the median of 70 across 45 interventional studies indexed under Vitamin B 12 Deficiency.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Medice Arzneimittel Pütter GmbH & Co KG is the lead sponsor of 10 studies on the registry; none are open to participants now.
Medice Arzneimittel Pütter GmbH & Co KG has 1 study filed under Vitamin B 12 Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary efficacy objective:
To investigate the effects of a parenterally vitamin B12 combination treatment versus an oral vitamin B12 mono therapy on the vitamin B12 status in female and male patients as determined by the change from baseline in serum vitamin B12 concentration after 4 weeks (28 days) of treatment.
Secondary efficacy objectives:
To evaluate the effects of a parenterally vitamin B12 combination versus an oral vitamin B12 mono therapy after 4 weeks of treatment on:
Safety objectives:
To evaluate the safety and tolerability of oral vitamin B12 mono therapy versus intramuscular vitamin B12 combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 injection twice weekly at the clinical site. Totally 8 injections through 4 week treatment period
Drug: Vitamin B12, Vitamin B6, Folic acid
1 oral tablet once daily in the morning. Totally 28 tablets at approximately the same time each day through 4 week treatment period
Drug: Vitamin B12 (Cyanocobalamin)
Drug pages: Vitamin B 12 · Vitamin B 6 · Pyridoxine · Folic Acid
A solution for intramuscular injection of fixed vitamin combination (5 mg vitamin B6, 1 mg B12 and 1,05 mg folic acid )
Also known as: Medivitan® iM
oral tablets of 1mg Vitamin B12
Also known as: B12 Ankermann®
Vitamin B12
Effects of treatment on serum vitamin B12
Time frame: Change from baseline at day 28
Holotranscobalamin
Effects of treatment on serum holotranscobalamin
Time frame: Change from baseline at day 28 and at follow up at day 56
Homocystein
Effects of treatment on serum homocystein
Time frame: Change from baseline at day 28 and at follow up at day 56
Methylmalonic acid
Effects of treatment on serum methylmalonic acid
Time frame: Change from baseline at day 28 and at follow up at day 56
Combined vitamin B12 marker (cB12)
Effects of treatment on cB12. Combined vitamin B12 markers (cB12) will be statistically calculated using the levels of Serum holotranscobalamin, Serum homocysteine, Serum methylmalonic acid. cB12 (cB12=log10\[(holoTC x B12)/(MMA x Hcy)\]-(age factor).
Time frame: Change from baseline at day 28 and at follow up at day 56
Serum S-adenosylmethione (SAM)
Effects of treatment on serum S-adenosylmethione (SAM)
Time frame: Change from baseline at day 28 and at follow up at day 56
Serum S-adenosylhomocysteine (SAH)
Effects of treatment on serum S-adenosylhomocysteine (SAH)
Time frame: Change from baseline at day 28 and at follow up at day 56
SAM/SAH ratio
The change of the ratio will be assessed statistically using the levels of Serum S-adenosylmethione (SAM) and Serum S-adenosylhomocysteine (SAH)
Time frame: Change from baseline at day 28 and at follow up at day 56
Quality of life assessed with SF-36
Effects of treatment on SF-36 questionnaire (from 0 to 100 points in each of the eight subscales, where the higher score means the higher quality of patient's life in each domain)
Time frame: Change from baseline at day 28 and at follow up at day 56
Quality of life assessed with WHO-5 questionnaire
Effects of treatment on WHO-5 questionnaire (from 0 to 25, where the higher score means the higher quality of patient's life)
Time frame: Change from baseline at day 28 and at follow up at day 56
Quality of life assessed with VAS EQ-5D
Effects of treatment on visual analogue scale EQ-5D (from 0 "the worst possible quality of life" to 10 "the best possible quality of life")
Time frame: From baseline to day 28 and at follow up at day 56
Safety objectives
The evaluation of safety will be conducted through a comprehensive analysis of adverse events.
Time frame: assessed through 56 days of patient's participation
Plan to share: Undecided
Ran from Apr 2025 to primary completion in Oct 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vitamin B 12 · Vitamin B 6 · Pyridoxine · Folic Acid
Medice Arzneimittel Pütter GmbH & Co KG